Enclosed please find herewith Audited financial results for the quarter and year ended March 31, 2026

EBITDA margin expansionExceptional itemResults View source PDF Explain this filing

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.9%Reaction day

₹1066.00

prior close

₹1060.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-2.5% vs market

Pharmaceuticals peers, median of 160sector-0.1%-2.8% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.9

15m

+0.4

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.9-0.4-2.5-0.1-2.8

Next day

-1.2-1.7+0.5-0.9-0.3

-0.4-1.3+0.9-0.2-0.2

-0.4-0.7+0.3+0.3-0.7

-0.6+0.4-1.0+1.1-1.6

-2.5+0.5-3.0+0.2-2.7

+2.1+2.8-0.7+1.0+1.2

15d

-6.3+1.2-7.5-0.2-6.1

-1.7+5.3-7.0+1.7-3.4

+9.9+9.9+0.0+7.7+2.2

+30.9+13.1+17.7+7.6+23.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alivus Life Sciences reported strong full-year results for FY2026. Revenue from operations grew 6.9% to Rs 25,518 million from Rs 23,869 million in FY2025. Profit after tax increased 16.2% to Rs 5,645 million from Rs 4,856 million. EBITDA margin expanded to approximately 31.6% from 29.5% in the prior year. The Board recommended a final dividend of Rs 5 per share (250% on face value of Rs 2). An exceptional item of Rs 256.57 million was recorded due to statutory impact of new labour codes (gratuity Rs 170 million and compensated absences Rs 86.55 million). Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion. Cash and cash equivalents declined sharply from Rs 711 million to Rs 20 million due to heavy capital expenditure of Rs 3,071 million.

Likely market impact

The company delivered healthy profit growth with margin expansion, indicating operational efficiency gains. The heavy capex spending reduced cash reserves but supports future growth. The clean audit opinion and dividend payout are positive signals for shareholders.